Our principal products in this category, Pediapred
in the USA and Coracten in the UK, both achieved double-digit growth in sales, with 1998 sales of (pound)6 million being achieved by both products.
With 185 sales people operating in 12 regional business units, our salesforce is of an appropriate size to support our highly targeted niche marketing strategy and its positive impact is becoming increasingly evident with promising growth in prescriptions written for Tussionex, Zaroxolyn and Pediapred in the second half of 1997.
The largest brands in this category are Pediapred in the USA and Coracten in the UK both of which achieved sales of 4.
2 million pound is due to three factors; sales in the US of Pediapred
, acquired from RPR; sales of new products acquired (from RPR) in France and (from Glaxo Wellcome) in Spain; and contract manufacturing at our Speke and Medevale sites.